日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Responses to Tetanus and Meningococcal Vaccines in Patients with Alopecia Areata Treated with Ritlecitinib

接受利特西替尼治疗的斑秃患者对破伤风和脑膜炎球菌疫苗的反应

Ishowo-Adejumo, Rahmat; Zareba, Agnieszka; Wajsbrot, Dalia; Wolk, Robert

Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO-2b/3 and ALLEGRO-LT Clinical Studies for Alopecia Areata

ALLEGRO-2b/3 和 ALLEGRO-LT 斑秃临床研究中,利特西替尼在亚洲亚人群中的疗效和安全性

Ueki, Rie; Mizuashi, Masato; Harada, Kazutoshi; Zhang, Xingqi; Wu, Wenyu; Chung, Wen-Hung; Kwon, Ohsang; Luo, Xin; Basey, Victoria; Wolk, Robert; Shi, Nanzhi; Fujita, Kayo; Shen, Yimeng; Hirose, Tomohiro

Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

更正:ALLEGRO临床试验项目中口服JAK3/TEC家族激酶抑制剂Ritlecitinib治疗斑秃的综合安全性分析

King, Brett; Soung, Jennifer; Tziotzios, Christos; Rudnicka, Lidia; Joly, Pascal; Gooderham, Melinda; Sinclair, Rodney; Mesinkovska, Natasha A; Paul, Carle; Gong, Yankun; Anway, Susan D; Tran, Helen; Wolk, Robert; Zwillich, Samuel H; Lejeune, Alexandre

Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial

接受利特西替尼治疗的患者中,通过斑秃患者优先结局指标评估的患者自述脱发及其影响:ALLEGRO 2b/3期随机临床试验

Sinclair, Rodney; Mesinkovska, Natasha; Mitra, Debanjali; Wajsbrot, Dalia; Law, Ernest H; Wolk, Robert; King, Brett

Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata

利特西替尼 50 mg 和 100 mg 治疗斑秃的新型 3 期外部和合成安慰剂对照临床试验的原理和设计

King, Brett; McMichael, Amy; Sinclair, Rodney; Vañó-Galvan, Sergio; Wolk, Robert; Woodworth, Deborah; Soma, Koshika; Robbana, Feriel; Lejeune, Alexandre; Napatalung, Lynne; Law, Ernest; Wajsbrot, Dalia; Wang, Cunshan; Roychoudhury, Satrajit

Rates of Infections, Malignancies, Cardiovascular Outcomes, and Death in Individuals with Hospital-treated Alopecia Areata: A Registry-based Cohort Study in Denmark

丹麦一项基于登记数据的队列研究:接受医院治疗的斑秃患者的感染率、恶性肿瘤发生率、心血管事件发生率和死亡率

Sørensen, Sissel Brandt Toft; George, Prethibha; Jagun, Oladayo; Wolk, Robert; Napatalung, Lynne; Zwillich, Samuel H; Iversen, Lars; Ehrenstein, Vera

Using patient preference to inform ritlecitinib dose selection for alopecia areata treatment

利用患者意愿指导利妥昔单抗治疗斑秃的剂量选择

Hauber, Brett; Whichello, Chiara; Mauer, Jonathan; Law, Ernest; Trapali, Myrto; Whalen, Edward; Wajsbrot, Dalia; Krucien, Nicolas; Tervonen, Tommi; Zwillich, Samuel H; Wolk, Robert

Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial

利特西替尼治疗亚洲斑秃患者的疗效和安全性:ALLEGRO 2b/3期试验的亚组分析

Zhang, Xingqi; Ye, Yanting; Sun, Weiling; Sheng, Youyu; Kinoshita-Ise, Misaki; Ito, Taisuke; Lan, Cheng-Che; Kwon, Ohsang; Schaefer, Gregor; Wolk, Robert; Hu, Shasha; Sun, Qiankun; Shen, Yimeng; Sakaki-Yumoto, Masayo

A Phase 1, Open-Label Study of the Pharmacokinetics of Ritlecitinib in Children Aged 6-12 Years With Alopecia Areata

一项针对6-12岁斑秃患儿的Ritlecitinib药代动力学的I期开放标签研究

Gonzalez, Mercedes E; Browning, John; Smith, Stacy; Plotka, Anna; Zhu, Jing Daisy; Parvatini, Shyam; Huh, Yeamin; Wolk, Robert

Microstructural assessment of the locus coeruleus‐entorhinal cortex pathway and association with ATN markers in patients with cognitive impairment

对认知障碍患者蓝斑-内嗅皮层通路微观结构进行评估,并探讨其与ATN标志物的关联

King, Brett; Soung, Jennifer; Tziotzios, Christos; Rudnicka, Lidia; Joly, Pascal; Gooderham, Melinda; Sinclair, Rodney; Mesinkovska, Natasha A; Paul, Carle; Gong, Yankun; Anway, Susan D; Tran, Helen; Wolk, Robert; Zwillich, Samuel H; Lejeune, Alexandre; Aiello, Marco; Borrelli, Pasquale; Cavaliere, Carlo; Marizzoni, Moira; Ribaldi, Federica; Garibotto, Valentina; Scheffler, Max; Jelescu, Ileana O; Jovicich, Jorge; Salvatore, Marco; Frisoni, Giovanni B; Pievani, Michela